What is DA Davidson’s Estimate for PBH Q3 Earnings?

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Research analysts at DA Davidson issued their Q3 2025 earnings estimates for Prestige Consumer Healthcare in a research note issued to investors on Monday, November 11th. DA Davidson analyst L. Weiser forecasts that the company will earn $1.16 per share for the quarter. DA Davidson currently has a “Buy” rating and a $95.00 target price on the stock. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.45 per share. DA Davidson also issued estimates for Prestige Consumer Healthcare’s FY2025 earnings at $4.46 EPS.

Prestige Consumer Healthcare (NYSE:PBH) last released its quarterly earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, meeting the consensus estimate of $1.09. The company had revenue of $283.79 million during the quarter, compared to analysts’ expectations of $282.09 million. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The business’s quarterly revenue was down .9% compared to the same quarter last year. During the same quarter in the prior year, the company earned $1.07 earnings per share.

Separately, Jefferies Financial Group reissued a “hold” rating and issued a $76.00 price objective (up previously from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. Two analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $94.20.

Prestige Consumer Healthcare Stock Performance

Shares of PBH stock opened at $82.32 on Tuesday. The company’s fifty day simple moving average is $72.84 and its 200-day simple moving average is $70.00. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The firm has a market cap of $4.07 billion, a PE ratio of 20.08, a P/E/G ratio of 2.30 and a beta of 0.47. Prestige Consumer Healthcare has a 12 month low of $56.61 and a 12 month high of $83.13.

Institutional Trading of Prestige Consumer Healthcare

Several institutional investors and hedge funds have recently added to or reduced their stakes in PBH. Opal Wealth Advisors LLC bought a new stake in Prestige Consumer Healthcare during the second quarter worth $26,000. Quest Partners LLC raised its position in shares of Prestige Consumer Healthcare by 2,826.7% in the second quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after purchasing an additional 424 shares during the period. EverSource Wealth Advisors LLC raised its position in shares of Prestige Consumer Healthcare by 80.6% in the first quarter. EverSource Wealth Advisors LLC now owns 466 shares of the company’s stock valued at $33,000 after purchasing an additional 208 shares during the period. Gladius Capital Management LP bought a new position in shares of Prestige Consumer Healthcare in the second quarter valued at about $35,000. Finally, Northwestern Mutual Wealth Management Co. raised its position in shares of Prestige Consumer Healthcare by 562.3% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the period. 99.95% of the stock is owned by institutional investors.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.